Combination therapy with a compound acting as a platelet adp receptor inhibitor
AssigneePortola Pharmaceuticals, Inc.
InventorsPamela B. Conley, Patrick Andre, Uma Sinha
Life of this patent
Estimating the term…
Abstract
The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.
Claims63
A method for treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of the following therapeutic agents:
- (1) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof;
- and
- (2) a therapeutic agent selected from the group consisting of an anticoagulant agent, an antiplatelet agent, and combinations thereof.
A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the following therapeutic agents:
- (1) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof;
- and
- (2) a therapeutic agent selected from the group consisting of an anticoagulant agent, an antiplatelet agent and combinations thereof.
A kit comprising:
- (1) a first container, wherein said first container contains [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof;
- and
- (2) a second container, wherein said second container contains an anticoagulant agent or another antiplatelet agent.
Dependencies are inferred from the claim text.